Archana Sasi, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypoalbuminemia | 1 | 2024 | 90 | 0.830 |
Why?
|
Bone Neoplasms | 3 | 2024 | 2567 | 0.810 |
Why?
|
Sarcoma | 2 | 2023 | 1802 | 0.770 |
Why?
|
Leiomyosarcoma | 1 | 2022 | 423 | 0.610 |
Why?
|
Retinal Neoplasms | 3 | 2024 | 147 | 0.580 |
Why?
|
Retinoblastoma | 3 | 2024 | 316 | 0.550 |
Why?
|
Osteosarcoma | 1 | 2022 | 909 | 0.540 |
Why?
|
Soft Tissue Neoplasms | 1 | 2023 | 1165 | 0.470 |
Why?
|
Antiemetics | 2 | 2024 | 185 | 0.370 |
Why?
|
Neoplasms | 6 | 2024 | 22340 | 0.340 |
Why?
|
India | 6 | 2024 | 2334 | 0.300 |
Why?
|
Remote Consultation | 1 | 2024 | 240 | 0.190 |
Why?
|
Purines | 1 | 2024 | 615 | 0.180 |
Why?
|
Quality of Life | 1 | 2022 | 13462 | 0.180 |
Why?
|
Aminopyridines | 1 | 2024 | 576 | 0.170 |
Why?
|
Information Systems | 1 | 2022 | 400 | 0.170 |
Why?
|
Immunity, Humoral | 1 | 2024 | 605 | 0.160 |
Why?
|
Benzimidazoles | 1 | 2024 | 864 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2024 | 3537 | 0.150 |
Why?
|
Immunity, Cellular | 1 | 2024 | 1555 | 0.150 |
Why?
|
Cost-Benefit Analysis | 3 | 2024 | 5526 | 0.130 |
Why?
|
Doxorubicin | 1 | 2022 | 2230 | 0.130 |
Why?
|
Combined Modality Therapy | 2 | 2024 | 8529 | 0.120 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 1560 | 0.110 |
Why?
|
Adolescent | 6 | 2024 | 88835 | 0.110 |
Why?
|
Child | 9 | 2024 | 80564 | 0.110 |
Why?
|
Antibodies, Viral | 1 | 2024 | 3211 | 0.100 |
Why?
|
Patient Satisfaction | 1 | 2024 | 3475 | 0.100 |
Why?
|
Developing Countries | 1 | 2024 | 2911 | 0.100 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 2895 | 0.100 |
Why?
|
Humans | 21 | 2024 | 765968 | 0.090 |
Why?
|
Vaccination | 1 | 2024 | 3426 | 0.090 |
Why?
|
Imaging, Three-Dimensional | 1 | 2024 | 4034 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1927 | 0.090 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13648 | 0.080 |
Why?
|
Consensus | 3 | 2024 | 3202 | 0.080 |
Why?
|
Vomiting | 2 | 2024 | 647 | 0.080 |
Why?
|
Retrospective Studies | 5 | 2024 | 81514 | 0.080 |
Why?
|
Prognosis | 2 | 2024 | 29922 | 0.070 |
Why?
|
Dexamethasone | 2 | 2024 | 1963 | 0.060 |
Why?
|
Young Adult | 4 | 2024 | 59889 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5753 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20659 | 0.060 |
Why?
|
Philadelphia Chromosome | 1 | 2023 | 119 | 0.050 |
Why?
|
Cancer Care Facilities | 1 | 2024 | 426 | 0.050 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2024 | 276 | 0.040 |
Why?
|
Nausea | 1 | 2024 | 680 | 0.040 |
Why?
|
Markov Chains | 1 | 2024 | 968 | 0.040 |
Why?
|
Treatment Refusal | 1 | 2024 | 433 | 0.040 |
Why?
|
Thorax | 1 | 2023 | 554 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2024 | 13451 | 0.040 |
Why?
|
Receptors, Progesterone | 1 | 2024 | 1153 | 0.040 |
Why?
|
Prospective Studies | 1 | 2024 | 54802 | 0.040 |
Why?
|
Morpholines | 1 | 2022 | 577 | 0.040 |
Why?
|
Female | 7 | 2024 | 396112 | 0.040 |
Why?
|
Actigraphy | 1 | 2022 | 532 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1737 | 0.040 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2024 | 1224 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2024 | 65188 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21056 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2024 | 2242 | 0.030 |
Why?
|
Male | 5 | 2024 | 363698 | 0.030 |
Why?
|
Polysomnography | 1 | 2022 | 1859 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26318 | 0.030 |
Why?
|
Caregivers | 1 | 2024 | 2307 | 0.020 |
Why?
|
Infant | 2 | 2024 | 36386 | 0.020 |
Why?
|
Child, Preschool | 2 | 2024 | 42500 | 0.020 |
Why?
|
Genetic Testing | 1 | 2024 | 3595 | 0.020 |
Why?
|
Survival Rate | 1 | 2024 | 12795 | 0.020 |
Why?
|
Age Factors | 1 | 2024 | 18380 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5696 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10383 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 8923 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8297 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5370 | 0.020 |
Why?
|
Sleep | 1 | 2022 | 4813 | 0.020 |
Why?
|
Lung | 1 | 2023 | 10033 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2024 | 26346 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 11868 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2024 | 39193 | 0.010 |
Why?
|
Cohort Studies | 1 | 2022 | 41649 | 0.010 |
Why?
|
Adult | 2 | 2024 | 223044 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 30198 | 0.010 |
Why?
|
Aged | 1 | 2024 | 171117 | 0.010 |
Why?
|
Middle Aged | 1 | 2024 | 223009 | 0.010 |
Why?
|